Patents by Inventor Gregory E. Hardee
Gregory E. Hardee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8691785Abstract: The present invention relates to compositions and methods which enhance the local and systemic uptake and delivery of oligonucleotides and nucleic acids via non-parenteral routes of administration. Pharmaceutical compositions comprising oligonucleotides disclosed herein include, for systemic delivery, emulsion and microemulsion formulations for a variety of applications and oral dosage formulations. It has also surprisingly been discovered that oligonucleotides may be locally delivered to colonic sites by rectal enemas and suppositories in simple solutions, e.g., neat or in saline. Such pharmaceutical compositions of oligonucleotides may further include one or more penetration enhancers for the transport of oligonucleotides and other nucleic acids across mucosal membranes.Type: GrantFiled: January 7, 2013Date of Patent: April 8, 2014Assignee: Isis Pharmaceuticals, Inc.Inventors: Ching-Leou Teng, Phillip Dan Cook, Lloyd Tillman, Gregory E. Hardee, David J. Ecker, Muthiah Manoharan
-
Patent number: 8377897Abstract: The present invention relates to compositions and methods which enhance the local and systemic uptake and delivery of oligonucleotides and nucleic acids via non-parenteral routes of administration. Pharmaceutical compositions comprising oligonucleotides disclosed herein include, for systemic delivery, emulsion and microemulsion formulations for a variety of applications and oral dosage formulations. It has also surprisingly been discovered that oligonucleotides may be locally delivered to colonic sites by rectal enemas and suppositories in simple solutions, e.g., neat or in saline. Such pharmaceutical compositions of oligonucleotides may further include one or more penetration enhancers for the transport of oligonucleotides and other nucleic acids across mucosal membranes.Type: GrantFiled: September 28, 2005Date of Patent: February 19, 2013Assignee: Isis Pharmaceuticals, Inc.Inventors: Ching-Leou Teng, Phillip Dan Cook, Lloyd Tillman, Gregory E. Hardee, David J. Ecker, Muthiah Manoharan
-
Patent number: 8168600Abstract: The present invention relates to compositions and methods which enhance the delivery of nucleic acids and other nucleosidic moieties via topical routes of administration. The invention relates to the use of an aqueous solution to preferentially deliver nucleic acids preferentially to hair follicles. The invention relates to a method of inhibiting hair growth comprising administration of a nucleic acid preferentially to a hair follicle.Type: GrantFiled: April 21, 2005Date of Patent: May 1, 2012Assignee: Isis Pharmaceuticals, Inc.Inventors: Sujatha Dokka, Scott Cooper, Susan Kelly, Gregory E. Hardee, James G. Karras
-
Publication number: 20110256217Abstract: Delayed release oral pharmaceutical formulations and methods for enhanced intestinal drug absorption. The formulation comprises a first population of carrier particles comprising a drug and a penetration enhancer which are released at a first location in the intestine, and a second population of carrier particles comprising a penetration enhancer and a delayed release coating or matrix. This penetration enhancer is released at a second location in the intestine downstream from the first location and enhances absorption of the drug when it reaches the second location.Type: ApplicationFiled: June 16, 2009Publication date: October 20, 2011Applicant: Isis Pharmaceuticals, Inc.Inventors: Susan Weinbach, Lloyd G. Tillman, Richard S. Geary, Gregory E. Hardee
-
Publication number: 20110213014Abstract: The present invention relates to compositions and methods which enhance the delivery of oligonucleotides and other nucleosidic moieties via topical routes of administration. Preferred compositions include liposomes or penetration enhancers for the delivery of such moieties to dermal and/or epidermal tissue in an animal for investigative, therapeutic or prophylactic purposes.Type: ApplicationFiled: May 13, 2011Publication date: September 1, 2011Applicant: Isis Pharmaceuticals, Inc.Inventors: Rahul C. Mehta, Gregory E. Hardee, Phillip Dan Cook, David J. Ecker, Yali Jennifer Tsai, Michael V. Templin
-
Patent number: 7964579Abstract: The present invention relates to compositions and methods which enhance the delivery of oligonucleotides and other nucleosidic moieties via topical routes of administration. Preferred compositions include liposomes or penetration enhancers for the delivery of such moieties to dermal and/or epidermal tissue in an animal for investigative, therapeutic or prophylactic purposes.Type: GrantFiled: August 21, 2009Date of Patent: June 21, 2011Assignee: Isis Pharmaceuticals, Inc.Inventors: Rahul C. Mehta, Gregory E. Hardee, Phillip Dan Cook, David J. Ecker, Yali Jennifer Tsai, Michael V. Templin
-
Publication number: 20090326045Abstract: The present invention relates to compositions and methods which enhance the delivery of oligonucleotides and other nucleosidic moieties via topical routes of administration. Preferred compositions include liposomes or penetration enhancers for the delivery of such moieties to dermal and/or epidermal tissue in an animal for investigative, therapeutic or prophylactic purposes.Type: ApplicationFiled: August 21, 2009Publication date: December 31, 2009Applicant: Isis Pharmaceuticals, Inc.Inventors: Rahul C. Mehta, Gregory E. Hardee, Phillip Dan Cook, David J. Ecker, Yali Jennifer Tsai, Michael V. Templin
-
Patent number: 7576067Abstract: Delayed release oral pharmaceutical formulations and methods for enhanced intestinal drug absorption. The formulation comprises a first population of carrier particles comprising a drug and a penetration enhancer which are released at a first location in the intestine, and a second population of carrier particles comprising a penetration enhancer and a delayed release coating or matrix. This penetration enhancer is released at a second location in the intestine downstream from the first location and enhances absorption of the drug when it reaches the second location.Type: GrantFiled: December 1, 2004Date of Patent: August 18, 2009Assignee: Isis Pharmaceuticals, Inc.Inventors: Susan Weinbach, Lloyd G. Tillman, Richard S. Geary, Gregory E. Hardee
-
Patent number: 6841539Abstract: The present invention relates to compositions and methods which enhance the delivery of oligonucleotides and other nucleosidic moieties via topical routes of administration. Preferred compositions include liposomes or penetration enhancers for the delivery of such moieties to dermal and/or epidermal tissue in an animal for investigative, therapeutic or prophylactic purposes.Type: GrantFiled: May 20, 1999Date of Patent: January 11, 2005Assignee: ISIS Pharmaceuticals, Inc.Inventors: Rahul C. Mehta, Gregory E. Hardee, Phillip Dan Cook, David J. Ecker, Yali Jennifer Tsai, Michael V. Templin
-
Publication number: 20040229831Abstract: The present invention relates to compositions and methods which enhance the local and systemic uptake and delivery of oligonucleotides and nucleic acids via non-parenteral routes of administration. Pharmaceutical compositions comprising oligonucleotides disclosed herein include, for systemic delivery, emulsion and microemulsion formulations for a variety of applications and oral dosage formulations. It has also surprisingly been discovered that oligonucleotides may be locally delivered to colonic sites by rectal enemas and suppositories in simple solutions, e.g., neat or in saline. Such pharmaceutical compositions of oligonucleotides may further include one or more penetration enhancers for the transport of oligonucleotides and other nucleic acids across mucosal membranes.Type: ApplicationFiled: March 4, 2004Publication date: November 18, 2004Applicant: ISIS Pharmaceuticals, Inc.Inventors: Ching-Leou Teng, Phillip Dan Cook, Lloyd Tillman, Gregory E. Hardee, David J, Ecker, Muthiah Manoharan
-
Patent number: 6747014Abstract: The present invention relates to compositions and methods which enhance the local and systemic uptake and delivery of oligonucleotides and nucleic acids via non-parenteral routes of administration. Pharmaceutical compositions comprising oligonucleotides disclosed herein include, for systemic delivery, emulsion and microemulsion formulations for a variety of applications and oral dosage formulations. It has also surprisingly been discovered that oligonucleotides may be locally delivered to colonic sites by rectal enemas and suppositories in simple solutions, e.g., neat or in saline. Such pharmaceutical compositions of oligonucleotides may further include one or more penetration enhancers for the transport of oligonucleotides and other nucleic acids across mucosal membranes.Type: GrantFiled: December 21, 2001Date of Patent: June 8, 2004Assignee: ISIS Pharmaceuticals, Inc.Inventors: Ching-Leou Teng, Phillip Dan Cook, Lloyd Tillman, Gregory E. Hardee, David J. Ecker, Muthiah Manoharan
-
Publication number: 20030124196Abstract: Delayed release oral pharmaceutical formulations and methods for enhanced intestinal drug absorption. The formulation comprises a first population of carrier particles comprising a drug and a penetration enhancer which are released at a first location in the intestine, and a second population of carrier particles comprising a penetration enhancer and a delayed release coating or matrix. This penetration enhancer is released at a second location in the intestine downstream from the first location and enhances absorption of the drug when it reaches the second location.Type: ApplicationFiled: August 22, 2001Publication date: July 3, 2003Inventors: Susan Weinbach, Lloyd G. Tillman, Richard S. Geary, Gregory E. Hardee
-
Publication number: 20030083286Abstract: Compositions and methods for enhanced intestinal drug absorption. The formulation comprises a first population of carrier particles comprising a drug and a bioadhesive compound and a second population of carrier particles comprising a penetration enhancer. The bioadhesive extends the residence time of the drug and its absorptive potential across the portion of the intestinal mucosa made permeable by the penetration enhancer.Type: ApplicationFiled: August 22, 2001Publication date: May 1, 2003Inventors: Ching-Leou Teng, Susan Weinbch, Lloyd G. Tillman, Richard S. Geary, Gregory E. Hardee
-
Publication number: 20030040497Abstract: The present invention relates to compositions and methods which enhance the local and systemic uptake and delivery of oligonucleotides and nucleic acids via non-parenteral routes of administration. Pharmaceutical compositions comprising oligonucleotides disclosed herein include, for systemic delivery, emulsion and microemulsion formulations for a variety of applications and oral dosage formulations. It has also surprisingly been discovered that oligonucleotides may be locally delivered to colonic sites by rectal enemas and suppositories in simple solutions, e.g., neat or in saline. Such pharmaceutical compositions of oligonucleotides may further include one or more penetration enhancers for the transport of oligonucleotides and other nucleic acids across mucosal membranes.Type: ApplicationFiled: December 21, 2001Publication date: February 27, 2003Inventors: Ching-Leou Teng, Phillip Dan Cook, Lloyd Tillman, Gregory E. Hardee, David J. Ecker, Muthiah Manoharan
-
Publication number: 20030027780Abstract: The present invention is related to non-parenteral multiparticulate formulations capable of transporting therapeutic, prophylactic and diagnostic agents across mucosal membranes such as gastrointestinal, buccal, nasal, rectal and vaginal. Formulations comprise a plurality of carrier particles, an agent to be delivered across a mucosal membrane, and a penetration enhancer. The drug is adhered to the surface of the carrier particle or is impregnated within by electrostatic, covalent or mechanical forces.Type: ApplicationFiled: February 8, 2002Publication date: February 6, 2003Inventors: Gregory E. Hardee, Lloyd G. Tillman, Maria Gonzalez-Ferreiro, Rahul C. Mehta, Ching-Leou Teng
-
Patent number: 6083923Abstract: Pharmaceutical compositions comprising sterically stabilized liposomes containing antisense oligonucleotides are provided for the modulation of expression of the human ras gene in both the normal (wildtype) and activated (mutant) forms.Type: GrantFiled: October 31, 1997Date of Patent: July 4, 2000Assignee: Isis Pharmaceuticals Inc.Inventors: Gregory E. Hardee, Richard S. Geary, Arthur Levin, Michael V. Templin, Randy Howard, Rahul C. Mehta
-
Patent number: 5721359Abstract: Anhydrous and crystalline free acid form of the cephalosporin antiobiotic ceftiofur, processes for its manufacture, and pharmaceutical composition containing it are provided.Type: GrantFiled: September 11, 1995Date of Patent: February 24, 1998